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The spike (S) protein of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) is not only responsible for receptor
binding, but also a major antigenic determinant capable of inducing protective immunity. In this study, we demonstrated that the receptor-
binding domain (RBD) of S protein is an important immunogenic site in patients with SARS and rabbits immunized with inactivated SARS-
CoV. Serum samples from convalescent SARS patients and immunized rabbits had potent neutralizing activities against infection by
pseudovirus expressing SARS-CoV S protein. Depletion of RBD-specific antibodies from patient or rabbit immune sera by
immunoadsorption significantly reduced serum-mediated neutralizing activity, while affinity-purified anti-RBD antibodies had relatively
higher potency neutralizing infectivity of SARS pseudovirus, indicating that the RBD of S protein is a critical neutralization determinant of
SARS-CoV during viral infection and immunization. Two monoclonal antibodies (1A5 and 2C5) targeting at the RBD of S protein were
isolated from mice immunized with inactivated SARS-CoV. Both 1A5 and 2C5 possessed potent neutralizing activities, although they
directed against distinct conformation-dependant epitopes as shown by ELISA and binding competition assay. We further demonstrated that
2C5, but not 1A5, was able to block binding of the RBD to angiotensin-converting enzyme 2 (ACE2), the functional receptor on targeted
cells. These data provide important information for understanding the antigenicity and immunogenicity of SARS-CoV and for designing
SARS vaccines.
D 2005 Elsevier Inc. All rights reserved.
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The global emergency of severe acute respiratory
syndrome (SARS) was caused by a new coronavirus
(SARS-CoV) (Drosten et al., 2003; Ksiazek et al., 2003;
Marra et al., 2003; Peiris et al., 2003; Rota et al., 2003).
Similar to other coronaviruses, SARS-CoV features a large
positive-stranded RNA genome that harbors open-reading0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.01.034
T Corresponding authors. Fax: +1 212 570 3099.
E-mail address: SJiang@NYBloodcenter.org (S. Jiang).frames (ORFs) encoding a large polyprotein required for
virus replication, four structural proteins (spike, S; envelop,
E; membrane, M; and nucleocapsid, N), and eight additional
polypeptides of unknown function (Marra et al., 2003; Rota
et al., 2003). SARS-CoV infection can trigger humoral and
cellular immune responses against viral proteins in humans.
The high rate of recovery from acute illness of SARS in the
absence of effective medical therapy and the low rate of re-
infection by SARS-CoV suggest that protective immunity is
achievable. Recent studies have demonstrated that sera from
convalescent-phase SARS patients contain high titers of
neutralizing antibodies against SARS-CoV (Nie et al., 2004;005) 74–82
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those of other coronaviruses, has been shown to be a major
antigenic determinant that induces neutralizing antibodies
and protective immunity (Bisht et al., 2004; Buchholz et al.,
2004; Bukreyev et al., 2004; Yang et al., 2004). A DNA
vaccine encoding the S protein induced SARS-CoV
neutralization and protective immunity in mice (Yang et
al., 2004). Depletion of T cells and antibody transfer
experiments revealed that protection was mediated by
neutralizing antibodies (Subbarao et al., 2004; Yang et al.,
2004), and protection can be achieved by sole adminis-
tration of neutralizing monoclonal antibodies specific for S
protein (Traggiai et al., 2004). Furthermore, vaccination of
animals with recombinant viruses, such as attenuated
vaccinia virus (MVA) and parainfluenza virus (BHPIV3),
that express S protein can elicit neutralizing antibodies to
protect animals against SARS-CoV challenge (Bisht et al.,
2004; Buchholz et al., 2004; Bukreyev et al., 2004).
Infection by pseudovirus expressing the SARS-CoV S
protein can be effectively neutralized by convalescent sera
from SARS patients (Nie et al., 2004; Simmons et al.,
2004). These data suggest that the S protein of SARS-CoV
is a promising candidate for developing SARS vaccines.
The S protein of SARS-CoV, a large class I trans-
membrane glycoprotein consisting of S1 domain (residues
15–680) and S2 domain (residues 681–1255), mediates
attachment of virions to susceptible cells and fusion of the
viral and cellular membranes (Hofmann and Pohlmann,
2004; Holmes, 2003). A 193-amino acid small fragment
(residues 318–510) in the S1 region was characterized as the
minimal receptor-binding domain (RBD) of SARS-CoV
(Babcock et al., 2004; Wong et al., 2004; Xiao et al., 2003).
RBD mediates S protein binding to angiotensin-converting
enzyme 2 (ACE2), the functional receptor for SARS-CoV
on susceptible cells (Dimitrov, 2003; Li et al., 2003;
Prabakaran et al., 2004; Wang et al., 2004). Most recently,
we demonstrated that the recombinant RBD of SARS-CoV
S protein could induce potent neutralizing antibodies (He et
al., 2004a, 2004b). In this report, we showed that the RBD
of S protein is a critical neutralization determinant of SARS-
CoV in SARS patients and SARS-CoV-immunized rabbits.
We further identified two neutralization epitopes in the RBD
by monoclonal antibodies (MAbs) isolated from mice
immunized with inactivated SARS-CoV.Fig. 1. Measurement of the RBD-specific antibodies in sera from
convalescent-phase SARS patients by ELISA. Recombinant RBD-C9 was
used for coating plates and the sera from 40 SARS patients and 30 healthy
blood donors were tested at 1:50 dilution. Sera were considered positive
when the optical density values were above the cutoff value (the mean
absorbance at 450 nm of sera from healthy blood donors plus three standard
deviations).Results
The RBD of S protein is an immunogenic site of SARS-CoV
in infected patients
It has been demonstrated that the RBD of S protein is
highly immunogenic in mice and rabbits immunized with
inactivated SARS-CoV (He et al., 2004b). In this study, 40
serum samples were collected from SARS patients at
convalescent phase to investigate the immunogenicity ofRBD in humans. All the sera were positive for SARS-CoV
as detected by ELISA with commercially available diag-
nostic kits, in which the mixture of proteins purified from
viral lysates of SARS-CoV was used as coating antigen
(data not shown). To determine antibodies specific for the
RBD of S protein in the SARS convalescent sera, we used
recombinant RBD-C9 as a coating antigen in ELISA. As
shown in Fig. 1, all of the 40 convalescent sera from SARS
patients reacted significantly with RBD-C9, whereas none
of the sera from healthy blood donors was reactive to this
antigen, suggesting that the RBD of SARS-CoV S protein is
highly immunogenic during virus infection.
Isolation of RBD-specific antibodies from convalescent sera
of SARS patients
The RBD-Fc fusion protein was used to isolate RBD-
specific antibodies by immunoaffinity chromatography
from the convalescent sera of SARS patients. Serum
samples from four SARS patients (SARS A–D) pre-
screened for high levels of reactivity against RBD-C9
and a control serum from health blood donor were ad-
sorbed on resins immobilized with RBD-Fc fusion protein,
and bound antibodies (anti-RBD) were eluted with pH 2.5
buffer. The efficiencies of depletion and recovery of the
RBD-specific antibodies were monitored by measuring the
reactivity of the starting human sera, the corresponding
flowthroughs, and eluted antibody fractions by ELISA
against the RBD-C9 and S1-C9. As shown in Fig. 2A, the
reactivity of anti-RBD in the sera of SARS patients was
efficiently removed by RBD-Fc affinity column. The
eluted anti-RBD antibodies could significantly react with
RBD-C9. All samples corresponding to the starting sera,
flowthroughs (anti-RBD depleted), and eluates (anti-RBD
Fig. 2. Isolation of RBD-specific antibodies from sera of convalescent-
phase SARS patients by immunoaffinity chromatography. Serum samples
were adsorbed to RBD-Fc columns and bound antibodies were eluted at pH
2.5. The patient sera, flowthroughs, and eluates were tested, respectively,
against RBD-C9 (A) and S1-C9 (B) at 1:50 dilution by ELISA. One serum
sample from a healthy blood donor was used as control.
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These suggest that the convalescent sera of SARS patients
contain abundant antibodies specific for S protein and the
RBD-specific antibodies can be specifically isolated by
immunoaffinity chromatography.
The RBD of S protein is a potent inducer of neutralizing
antibodies in infected patients
Entry of SARS-CoV into target cells is initiated by
binding of its S protein via RBD in the S1 region to ACE2, a
cellular receptor. It has been shown that a fusion protein
(RBD-Fc) containing the RBD of S protein is a potent
inducer of neutralizing antibodies against SARS-CoV in
immunized animals (He et al., 2004a). It is interesting to
know whether the RBD of S protein can mediate antibody
responses responsible for virus neutralization in infected
SARS patients. Therefore, the neutralizing activity of the
samples of the starting sera, flowthroughs, and eluates was
determined using SARS pseudovirus. Strikingly, the neu-
tralizing activity of patient sera was significantly reduced
after depletion of anti-RBD antibodies. The anti-RBD
antibodies in the eluates possessed higher potency thanthe antibodies in the flowthroughs to neutralize SARS
pseudovirus (Fig. 3 and Table 1), suggesting that more than
50% neutralizing activity in the convalescent sera of SARS
patients was contributed by the RBD-specific antibodies. In
contrast, the serum samples including the starting sera,
flowthroughs, and eluates from the healthy blood donor had
no neutralizing activities to same pseudovirus (data not
shown). These data indicate that the RBD of S protein is an
important inducer of neutralizing antibodies during viral
infection.
The RBD of S protein is a critical antigenic site to induce
neutralizing antibodies in rabbits immunized with
inactivated SARS-CoV
We previously demonstrated that the inactivated SARS-
CoV was able to induce neutralizing antibodies in the
immunized rabbits (He et al., 2004b). To further elucidate
neutralization determinants of the SARS-CoV, the RBD-
specific antibodies were isolated by immunoaffinity chro-
matography from four rabbit antisera (A–D). Similarly, the
reactivity of anti-RBD antibodies in the rabbit antisera could
be efficiently depleted by RBD-Fc affinity column, since the
flowthroughs did not bind to RBD-Fc while the eluted anti-
RBD antibodies significantly reacted with the RBD-Fc
(Fig. 4A). Samples corresponding to the starting sera, flow-
throughs (anti-RBD depleted sera), and eluates containing
anti-RBD antibodies had similar reactivity with the S1-C9
(Fig. 4B). The neutralizing activity of anti-RBD antibody-
depleted rabbit antisera was much lower than the starting
sera, while anti-RBD antibodies possessed more potent
activity to neutralize SARS pseudovirus (Fig. 4C and
Table 1). These data suggest that the RBD of S protein is
an effective inducer of neutralizing antibodies in virus-
immunized rabbits.
Isolation and characterization of MAbs against the RBD of
S protein
It has been shown that inactivated SARS-CoV can
induce high titers of antibodies specific for the RBD of S
protein in immunized mice (He et al., 2004b). To identify
neutralization epitopes of SARS-CoV, two MAbs (1A5 and
2C5) targeting at the RBD of S protein were isolated from
mice immunized with inactivated SARS-CoV. Epitope
specificities of 1A5 (IgG1/n) and 2C5 (IgG1/n) were
initially determined by ELISAs using RBD-Fc, DTT-
reduced RBD-Fc, S1-C9, and DTT-reduced S1-C9 as
coating antigens (Figs. 5A and B). Both MAbs were
reactive with native RBD-Fc and S1-C9, but not DTT-
reduced RBD-Fc and S1-C9, indicating that they were
directed against disulfide bond-dependent conformational
epitopes expressed on the RBD of S protein. These two
MAbs did not compete each other in an ELISA-based
binding competition assay (Fig. 5C), suggesting their
epitopes locate at different sites in the RBD.
Fig. 3. Neutralizing activity of the RBD-specific antibodies isolated from the sera of SARS patients. (A) SARS-A; (B) SARS-B; (C) SARS-C; and (D) SARS-
D. Inhibition of SARS pseudovirus infectivity in 293T/ACE2 cells by patient sera, flowthroughs, and eluates, respectively, at a series of 2-fold dilutions was
determined and the percentage of neutralization was calculated for each sample.
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293T/ACE2 cells as measured by flow cytometry. We tested
whether the RBD-specific MAbs inhibit binding of RBD-Fc
to cell-associated ACE2. As shown in Fig. 6, 2C5, but not
1A5, was able to block RBD-Fc binding to 293T/ACE2
cells. This result suggests that 2C5 recognizes an epitope
that may overlap with the receptor-binding sites in the S
protein, while 1A5 directs against a distinct conformation-
dependant epitope that is not involve in receptor binding.
With a single-cycle infection assay, we tested the neutraliz-
ing activities of these two MAbs against SARS pseudovirus.
Strikingly, 1A5 and 2C5 potently neutralized SARS
pseudovirus with 50% neutralization dose (ND50) at 0.048
Ag/ml and 0.097 Ag/ml, respectively (Fig. 7), suggestingTable 1
Neutralizing activity of serum samples against SARS pseudovirus
Sera sample Neutralization titer (ND50)
a
Starting sera Flowthroughs Eluates
Human sera
SARS-A 2812 945 1694
SARS-B 4999 1718 2670
SARS-C 3031 796 1822
SARS-D 2614 907 1052
Rabbit sera
A 2202 750 1250
B 1966 845 1125
C 2142 772 1050
D 1868 698 980
a ND50: Titer of a serum sample to yield 50% neutralization.that both conformation-dependant epitopes in the RBD of S
protein can elicit potent neutralizing antibodies.Discussion
The S protein of SARS-CoV is able to induce protective
immunity in immunized animals (Bisht et al., 2004;
Buchholz et al., 2004; Bukreyev et al., 2004; Yang et al.,
2004). Using a set of overlapping peptides that cover the
entire sequence of S protein, we have identified several
immunodominant domains within S protein. However, none
of these domains modeled by linear peptides were able to
elicit neutralizing antibodies (He et al., 2004c). In contrast,
the RBD (residues 318–510) in the S1 region of S protein
can induce highly potent neutralizing antibodies against the
SARS-CoV (He et al., 2004a, 2004b). Here, we have further
demonstrated that the RBD of SARS-CoV S protein is an
immunogenic site to induce antibody responses in SARS-
CoV-infected patients and immunized rabbits. With an
immunoabsorption assay, we have demonstrated that anti-
RBD antibodies function as a main population of neutraliz-
ing antibodies, suggesting that the RBD of S protein is an
important neutralization determinant of SARS-CoV.
The first essential step of coronavirus infection is the
interaction of S protein via the RBD with specific cellular
receptor. The RBDs on the S proteins of other coronavi-
ruses, such as mouse hepatitis virus (MHV), transmissible
gastroenteritis virus (TGEV), and human coronavirus
Fig. 4. Isolation and characterization of RBD-specific antibodies from
rabbit antisera by immunoaffinity chromatography. Reactivities of rabbit
antibodies with RBD-Fc (A) and S1-C9 (B) were tested at 1:50 dilution by
ELISA. (C) Neutralizing activity of the RBD-specific antibodies isolated
from rabbit antisera. Inhibition of SARS pseudovirus infection in 293T/
ACE2 cells by rabbit antisera, flowthroughs, and eluates, respectively, at a
series of 2-fold dilutions was determined and the percent neutralization was
calculated for each sample.
Fig. 5. Characterization of the RBD-specific MAbs. The reactivities of
MAbs against RBD-Fc (A) and S1-C9 (B) were tested by ELISA. MAbs
were tested at 10 Ag/ml, and control sera were tested at 1:100 dilution. (C)
Inhibition of biotinylated MAbs binding to RBD-Fc by RBD-specific
MAbs measured by competitive ELISA. Competing MAbs were tested at
100 Ag/ml.
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capable of inducing neutralizing antibodies (Bonavia et al.,
2003; Godet et al., 1994; Kubo et al., 1994). We
previously demonstrated that inactivated SARS-CoV vac-
cine was capable of inducing high titers of RBD-specific
antibodies that block receptor binding and virus entry (He
et al., 2004b). In the present study, two neutralization
epitopes in the RBD of S protein have been identified with
MAbs isolated from mice immunized with inactivatedSARS-CoV. Therefore, the RBD of S protein may serve as
an important target site for developing SARS vaccines and
immunotherapeutics.
Inactivated SARS-CoV has been used as one of the major
vaccine candidates and is currently being tested in clinical
trial in China (Marshall and Enserink, 2004). However,
caution should be taken in using the inactivated SARS-CoV
as vaccine since it contains a number of viral components that
may induce harmful immune and/or inflammatory responses
(Enserink, 2004; He et al., 2004c; Oba, 2003; Wang and Lu,
Fig. 6. Inhibition of RBD-Fc binding to ACE2 by MAbs. Inhibitory activity
of MAbs on RBD-Fc binding to cell-associated ACE2 expressed on 293T/
ACE2 cells was measured by flow cytometry. RBD-Fc and MAbs were
used at 1 and 50 Ag/ml, respectively.
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CoV vaccine triggered an autoimmune response against the
carbohydrate moieties in an abundant human serum glyco-
protein asialo-orosomucoid (Wang et al., 2004). Recombi-
nant viruses or DNA vaccines that express full-length S
protein have also been considered as SARS vaccine
candidates (Bisht et al., 2004; Buchholz et al., 2004;
Bukreyev et al., 2004; Yang et al., 2004). However, the
full-length S protein also contains several linear immunodo-
minant domains that induce a high titer of non-neutralizing
antibodies (He et al., 2004c). It is unclear whether or not these
non-neutralizing antibodies may enhance SARS-CoV infec-
tion or mediate harmful immune responses. It was reported
that vaccination of ferrets with vaccinia virus-based SARS
vaccine expressing full-length S protein aggravated liver
damage caused by SARS-CoV infection (Enserink, 2004;
Weingartl et al., 2004). It has been demonstrated that the S
protein of feline coronavirus (FIPV) expressed by recombi-
nant vaccinia can cause antibody-dependant enhancement of
disease if the vaccinated animals are subsequently infected
with wild-type virus (Corapi et al., 1992; Olsen et al., 1993;
Vennema et al., 1990).
Therefore, we propose to use the RBD of SARS-CoV S
protein for developing an effective and safe subunit vaccine,
since the RBD of S protein is not only a functional domain
that mediates virus-receptor binding, but also a critical
neutralization determinant of SARS-CoV. If an effective
RBD-based SARS vaccine can be developed, it may provide
a promising example for designing vaccines against other
viruses.Fig. 7. Neutralization of SARS pseudovirus infection in 293T/ACE2 cells
by MAbs. Each of the MAbs was tested at a series of 2-fold dilutions and
percent neutralization was calculated.Materials and methods
Expression of recombinant S proteins
Recombinant S proteins of SARS-CoV (Tor2 strain)
were expressed as previously described (He et al., 2004a,2004b). Plasmids encoding a 193-amino acid fragment of
RBD (residues 318–510) linked to the Fc domain of
human IgG1 (designated RBD-Fc) or tagged with C9
(designated RBD-C9) and plasmid encoding residues 12–
672 corresponding to the S1 domain of S protein tagged
with C9 at the C-terminus (designated S1-C9) were kindly
provided by Dr. M. Farzan at the Harvard Medical School
(Li et al., 2003; Wong et al., 2004). RBD-Fc, RBD-C9,
and S1-C9 proteins were expressed in 293T cells trans-
fected with the plasmids using Fugene 6 reagents
(Boehringer Mannheim, Indianapolis, IN) according to
the manufacturer’s protocol. Supernatants were harvested
72 h post-transfection. RBD-C9 and S1-C9 were purified
by affinity chromatography with anti-C9 MAb 1D4
(National Cell Culture Center, Minneapolis, MN). RBD-
Fc was purified by Protein A Sepharose 4 Fast Flow
(Amersham Biosciences, Piscataway, NJ).
Serum samples from SARS patients
Serum samples were collected from 40 convalescent
SARS patients 30–60 days after the onset of symptoms
based on clinical diagnosis during the SARS epidemics in
Beijing in 2003. The diagnostic criteria for SARS-CoV
infection followed the clinical description of SARS released
by WHO. All of the sera were heat-inactivated at 56 8C
prior to performing the experiments and verified to be
positive for SARS-CoV as detected by immunofluorescence
assay (IFA) and enzyme-linked immunoabsorbed assay
(ELISA) using commercially available diagnostic kits (Bei-
jing Genomics Institute, Beijing). Sera collected from 30
healthy blood donors were used as controls.
Immunization of rabbits with inactivated SARS-CoV
Inactivated SARS-CoV was prepared as described
previously (He et al., 2004b, 2004c). Briefly, SARS-CoV
strain BJ01 was propagated in Vero-E6 cells and inactivated
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desalting with Sephadex G-50, concentrated with PEG-
8000, and filtrated with Sepharose-CL 2B sequentially. The
purified viral particles were at N95% purity by HPLC
analysis. Four NZW rabbits were primarily immunized
intradermally with 30 Ag of purified inactivated viruses as
immunogen in the presence of complete Freund’s adjuvant
(FCA) and boosted twice with same amount freshly
prepared emulsion of the immunogen and Freund’s incom-
plete adjuvant (FIA) at 2-week intervals. Pre-immune sera
were collected before the primary immunization and
antisera were collected 5 days after the second boost.
Immunoaffinity chromatography
Immunoaffinity resins were prepared by coupling the
RBD-Fc fusion protein to cyanogen bromide-activated
Sepharose beads (Pharmacia, Piscataway, NJ) according
to the manufacturer’s instructions. For immunoadsorption,
human or rabbit serum samples were diluted 10-fold with
PBS and incubated with the RBD-Fc resin overnight at 4
8C with constant rotation. Resins were then packed into
columns and the flowthroughs (anti-RBD depleted) were
collected. After washing with 10 column volumes of PBS,
the bound antibodies (anti-RBD) were eluted in 0.2 M
glycine–HCl buffer, pH 2.5. The low-pH eluates were
neutralized immediately with pH 9.0 Tris buffer, and
bovine serum albumin (100 Ag/ml) was added for
stabilization. Buffer was exchanged with PBS by several
cycles of dilution and concentration on Amicon Ultra-15
centrifugal filter device (Millipore Corporation, Bedford,
MA). All samples were adjusted to the original volume of
serum and sterilized with 0.2-Am pore size microspin
filters (Millipore).
Isolation of monoclonal antibodies (MAbs)
BALB/C mice were immunized with inactivated SARS-
CoV as described previously (He et al., 2004b, 2004c).
Hybridomas for producing MAbs were generated using
standard protocol. Briefly, the splenocytes from immunized
mice were harvested and fused with SP2/0 myeloma cells.
Cell culture supernatants from wells containing hybridoma
colonies were screened by IFA. Cells from positive wells
were expanded and retested. Cultures that remained positive
were subcloned to generate stable hybridoma cell lines.
Mouse ascites was generated by injecting BALB/c mice
with hybridomas, and the MAbs were purified from mouse
ascites by Protein A Sepharose 4 Fast Flow (Amersham
Biosciences). The isotypes of mAbs were determined with
Mouse MonoAb-ID Kit (Zymed, South San Francisco, CA).
ELISA and binding competition
Human or rabbit serum samples and mouse MAbs
were tested against the recombinant S proteins (RBD-C9,RBD-Fc, or S1-C9) by ELISA, respectively. Briefly, 1 Ag/
ml of each recombinant protein was coated to 96-well
microtiter plates (Corning Costar, Acton, MA) in 0.1 M
carbonate buffer (pH 9.6) at 4 8C overnight. After
blocking with 2% non-fat milk, diluted samples were
added and incubated at 37 8C for 1 h, followed by three
washes with PBS containing 0.1% Tween 20. Bound
antibodies were detected with HRP-conjugated goat anti-
human IgG or goat anti-rabbit IgG or goat anti-mouse IgG
(Zymed, South San Francisco, CA), respectively, at 37 8C
for 1 h, followed by washes. The reaction was visualized
by addition of the substrate 3,3V,5,5V-tetramethylbenzidine
(TMB) and absorbance at 450 nm (A450) was measured
by an ELISA plate reader (Tecan US, Research Triangle
Park, NC).
To determine the effect of disulfide bond reduction on the
binding of RBD-specific MAbs, ELISA plate was coated
with recombinant RBD-Fc or S1-C9 at a concentration of 1
Ag/ml and then treated for 1 h at 37 8C with dithiothreitol
(DTT) at a concentration of 10 mM, followed by washes.
Then the wells were treated with 50 mM iodoacetamide for
1 h at 37 8C. After washes, a standard ELISAwas performed
as described above.
A competitive ELISA was performed to determine the
inhibitory activity of the RBD-specific MAbs on binding of
the biotinylated MAbs to RBD-Fc. Briefly, the wells of
ELISA plates were coated with RBD-Fc at 1 Ag/ml as
described above. A mixture of 50 Ag/ml of an unlabeled
MAb and 1 Ag/ml of a biotinylated MAb was added,
followed by incubation at 37 8C for 1 h. Binding of the
biotinylated MAbs was detected after addition of HRP-
conjugated streptavidin (Zymed) and TMB sequentially.
Biotinylation of MAbs was performed using the EZ-link
NHS-PEO Solid Phase Biotinylation Kit (Pierce, Rockford,
IL) according to the manufacturer’s protocol.
Inhibition of receptor-binding
Inhibition of MAbs on RBD-Fc binding to ACE2-
expressing cells was measured by flow cytometry. Briefly,
106 293T/ACE2 cells were detached, collected, and washed
with Hank’s balanced salt solution (HBSS) (Sigma, St.
Louis, MO). RBD-Fc was added to the cells to a final
concentration of 1 Ag/ml in the presence or absence of 50
Ag/ml MAbs, followed by incubation at room temperature
for 30 min. Cells were washed with HBSS and incubated
with anti-human IgG-FITC conjugate (Zymed) at 1:50
dilution at room temperature for an additional 30 min.
After washing, cells were fixed with 1% formaldehyde in
PBS and analyzed in a Becton FACSCalibur flow cytometer
(Mountain View, CA) using CellQuest software.
Neutralization of SARS pseudovirus infection
SARS pseudovirus was prepared as previously described
(He et al., 2004a, 2004b). In brief, 293T cells were co-
Y. He et al. / Virology 334 (2005) 74–82 81transfected with a plasmid encoding codon-optimized S
protein of SARS-CoV (Tor2 strain) and a plasmid encoding
Env-defective, luciferase-expressing HIV-1 genome (pNL4-
3.luc.RE) using Fugene 6 reagents (Boehringer Mannheim).
Supernatants containing pseudovirus bearing SARS-CoV S
protein were harvested 48 h post-transfection and used for
single-cycle infection of ACE2-transfected 293T cells.
Briefly, ACE2-expressed 293T cells were plated (104
cells/well) in 96-well tissue-culture plates and grown
overnight. The pseudovirus was preincubated with 2-fold
serially diluted serum samples or MAbs at 37 8C for 1 h
before addition to cells. The culture was re-fed with fresh
medium 24 h later and incubated for an additional 48 h.
Cells were washed with PBS and lysed using lysis reagent
included in the luciferase kit (Promega, Madison, WI).
Aliquots of cell lysates were transferred to 96-well Costar
flat-bottom luminometer plates (Corning Costar, Corning,
NY), followed by addition of luciferase substrate (Pro-
mega). Relative light units were determined immediately on
the Ultra 384 luminometer (Tecan US).Acknowledgment
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